Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

A yearslong Federal Trade Commission probe, resulting in a report released in July, reported that of the six pharmacy benefit ...

In the days leading up to President Trump’s inauguration, the Biden FTC rushed to initiate major lawsuits and to tie a bow on ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

When talking about the influence of pharmacy benefit managers, U.S. Sen. James Lankford exhibits a mastery of how companies like CVS Health control where patients get their medicine, what ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.